FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308803455> ?p ?o ?g. }

• W4308803455 abstract "Aims: Inflammatory biomarkers may play vital roles in the pathophysiology of diabetes and diabetic cardiorenal complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a potential cardiovascular and renal protective effect in type 2 diabetes. The aim of this meta-analysis was to quantify the effects of SGLT2 inhibitors on biomarkers of inflammation in randomized controlled trials (RCTs). Methods: PubMed, Cochrane Library, EMBASE, and Web of Science were searched for eligible RCTs of adults with type 2 diabetes (T2D) with no time limit (updated to 12 October 2022). The biomarkers selected included C-reactive protein (CRP), interleukin-6, tumor necrosis factor-alpha, leptin, adiponectin, ferritin, plasminogen activator inhibitor (PAI)-1, and vascular cell adhesion molecule-1. Data were analyzed using a random-effect model in Review Manager 5.4. Results: Thirty-four studies with 6,261 patients (68.6% male) were eligible for this meta-analysis. The mean age of the participants was 62.57(±11.13) years old, and the median treatment duration length with follow-up was 24 weeks. Generally, the included trials were of good methodological quality. The meta-analysis revealed that ferritin levels were significantly reduced in SGLT2 inhibitor treatment groups versus placebo or standard diabetes therapies (SMD: −1.21; 95% CI: −1.91, −0.52, p &lt; 0.001). The effects of CRP (SMD: 0.25; 95% CI: −0.47, −0.03, p = 0.02) and leptin (SMD: −0.22; 95% CI: −0.43, −0.01, p = 0.04) were reduced, and the effects of adiponectin were improved (SMD: 0.28; 95% CI: 0.15, 0.41, p &lt; 0.001) in placebo-controlled studies. PAI-1 levels were significantly reduced in studies controlled for diabetes therapies (SMD: −0.38; 95% CI: −0.61, −0.15, p = 0.001). Conclusion: This analysis provides strong evidence supporting anti-inflammatory effects of SGLT2 inhibitors in T2D subjects. The mechanisms and possible targets for the inflammation reducing and cardiorenal protective properties of SGLT2 inhibitors remain to be explored." @default.
• W4308803455 created "2022-11-15" @default.
• W4308803455 creator A5021384155 @default.
• W4308803455 creator A5032868943 @default.
• W4308803455 creator A5043994794 @default.
• W4308803455 creator A5052441498 @default.
• W4308803455 creator A5052579493 @default.
• W4308803455 creator A5055080959 @default.
• W4308803455 creator A5056246750 @default.
• W4308803455 creator A5059922337 @default.
• W4308803455 date "2022-11-11" @default.
• W4308803455 modified "2023-10-11" @default.
• W4308803455 title "The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials" @default.
• W4308803455 cites W1595418935 @default.
• W4308803455 cites W1979585690 @default.
• W4308803455 cites W2001991301 @default.
• W4308803455 cites W2074422939 @default.
• W4308803455 cites W2092483302 @default.
• W4308803455 cites W2098923148 @default.
• W4308803455 cites W2149053203 @default.
• W4308803455 cites W2166304122 @default.
• W4308803455 cites W2301210108 @default.
• W4308803455 cites W2488108349 @default.
• W4308803455 cites W2551376414 @default.
• W4308803455 cites W2563743072 @default.
• W4308803455 cites W2569505713 @default.
• W4308803455 cites W2588681363 @default.
• W4308803455 cites W2601727933 @default.
• W4308803455 cites W2619744261 @default.
• W4308803455 cites W2626446274 @default.
• W4308803455 cites W2734312801 @default.
• W4308803455 cites W2742155329 @default.
• W4308803455 cites W2774743973 @default.
• W4308803455 cites W2781483265 @default.
• W4308803455 cites W2789639012 @default.
• W4308803455 cites W2790286202 @default.
• W4308803455 cites W2790579026 @default.
• W4308803455 cites W2791162071 @default.
• W4308803455 cites W2904719418 @default.
• W4308803455 cites W2913223653 @default.
• W4308803455 cites W2916700999 @default.
• W4308803455 cites W2917271957 @default.
• W4308803455 cites W2921017081 @default.
• W4308803455 cites W2936957852 @default.
• W4308803455 cites W2944568480 @default.
• W4308803455 cites W2964946260 @default.
• W4308803455 cites W2966426030 @default.
• W4308803455 cites W2967006081 @default.
• W4308803455 cites W2973671909 @default.
• W4308803455 cites W2981565698 @default.
• W4308803455 cites W3007180795 @default.
• W4308803455 cites W3017135149 @default.
• W4308803455 cites W3019568499 @default.
• W4308803455 cites W3021818034 @default.
• W4308803455 cites W3030200182 @default.
• W4308803455 cites W3037876601 @default.
• W4308803455 cites W3041394830 @default.
• W4308803455 cites W3046854283 @default.
• W4308803455 cites W3048562226 @default.
• W4308803455 cites W3082758064 @default.
• W4308803455 cites W3093992036 @default.
• W4308803455 cites W3118258741 @default.
• W4308803455 cites W3121311184 @default.
• W4308803455 cites W3128876677 @default.
• W4308803455 cites W3129290046 @default.
• W4308803455 cites W3129673539 @default.
• W4308803455 cites W3135562266 @default.
• W4308803455 cites W3139057924 @default.
• W4308803455 cites W3139496483 @default.
• W4308803455 cites W3147549241 @default.
• W4308803455 cites W3155933028 @default.
• W4308803455 cites W3167353726 @default.
• W4308803455 cites W3174290103 @default.
• W4308803455 cites W3187559426 @default.
• W4308803455 cites W3196523672 @default.
• W4308803455 cites W3204012661 @default.
• W4308803455 cites W4205336217 @default.
• W4308803455 cites W4206082388 @default.
• W4308803455 cites W4206358667 @default.
• W4308803455 cites W4206799195 @default.
• W4308803455 cites W4211027395 @default.
• W4308803455 cites W4211206598 @default.
• W4308803455 cites W4214694796 @default.
• W4308803455 cites W4280549607 @default.
• W4308803455 cites W4294751438 @default.
• W4308803455 cites W4295295994 @default.
• W4308803455 cites W4295678552 @default.
• W4308803455 cites W4297092836 @default.
• W4308803455 doi "https://doi.org/10.3389/fphar.2022.1045235" @default.
• W4308803455 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36467062" @default.
• W4308803455 hasPublicationYear "2022" @default.
• W4308803455 type Work @default.
• W4308803455 citedByCount "3" @default.
• W4308803455 countsByYear W43088034552023 @default.
• W4308803455 crossrefType "journal-article" @default.
• W4308803455 hasAuthorship W4308803455A5021384155 @default.
• W4308803455 hasAuthorship W4308803455A5032868943 @default.
• W4308803455 hasAuthorship W4308803455A5043994794 @default.
• W4308803455 hasAuthorship W4308803455A5052441498 @default.
• W4308803455 hasAuthorship W4308803455A5052579493 @default.

• next